Valeo Financial Advisors LLC purchased a new stake in shares of Corteva (NYSE:CTVA) during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 4,177 shares of the company’s stock, valued at approximately $117,000.
Several other hedge funds have also made changes to their positions in CTVA. Vanguard Group Inc. bought a new stake in Corteva during the 2nd quarter worth approximately $1,803,496,000. BlackRock Inc. bought a new position in shares of Corteva in the 2nd quarter worth $1,728,215,000. Barrow Hanley Mewhinney & Strauss LLC bought a new position in shares of Corteva in the 2nd quarter worth $579,764,000. Nuveen Asset Management LLC bought a new position in shares of Corteva in the 2nd quarter worth $429,256,000. Finally, Price T Rowe Associates Inc. MD bought a new position in shares of Corteva in the 2nd quarter worth $404,071,000. Institutional investors own 72.18% of the company’s stock.
Shares of CTVA traded down $0.96 on Friday, reaching $25.81. The company’s stock had a trading volume of 39,865 shares, compared to its average volume of 4,368,057. The company’s 50 day moving average price is $28.05. Corteva has a 12-month low of $24.35 and a 12-month high of $32.78.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Friday, November 29th will be issued a $0.13 dividend. This represents a $0.52 dividend on an annualized basis and a dividend yield of 2.01%. The ex-dividend date is Wednesday, November 27th.
In other news, Director Klaus A. Engel purchased 18,393 shares of the stock in a transaction on Friday, August 30th. The shares were acquired at an average price of $30.00 per share, with a total value of $551,790.00. Following the completion of the acquisition, the director now directly owns 25,253 shares of the company’s stock, valued at $757,590. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Timothy P. Glenn purchased 6,500 shares of the stock in a transaction on Monday, August 5th. The shares were purchased at an average cost of $30.52 per share, for a total transaction of $198,380.00.
CTVA has been the subject of a number of research reports. Deutsche Bank upped their price objective on shares of Corteva from $32.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Monness Crespi & Hardt began coverage on shares of Corteva in a research report on Wednesday, July 17th. They issued a “sell” rating and a $24.00 target price for the company. Citigroup dropped their target price on shares of Corteva from $34.50 to $31.00 and set a “buy” rating for the company in a research report on Wednesday, October 9th. Argus began coverage on shares of Corteva in a research report on Thursday, June 20th. They issued a “hold” rating for the company. Finally, Barclays reaffirmed a “hold” rating and issued a $35.00 target price on shares of Corteva in a research report on Sunday, August 4th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and eight have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $31.93.
Corteva, Inc provides agriculture products worldwide. The company develops and supplies germplasm and traits in corn, soybean, and sunflower seed markets. It also supplies products to the agricultural input industry that protect against weeds, insects and other pests, and diseases, as well as to enhance crop health.
Recommended Story: What is the balance sheet?
Want to see what other hedge funds are holding CTVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corteva (NYSE:CTVA).
Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.